|
1.
|
The impact of losartan on the lifetime incidence of ESRD and costs in Mexico
Arredondo,Armando - Burke,Thomas A - Carides,George W - Lemus,Edith - Querol,Julio
| Formato: |
journal article |
| Enlaces: |
 
Background. The RENAAL (Reduction of Endpoints in Type 2 Diabetes with the Angiotensin II Antagonist Losartan) study demonstrated that treatment with losartan reduced the risk of ESRD by 29% among hypertensive patients with type 2 diabetes and diabetic nephropathy. The…
|
| Fecha: |
2005-06-01 |
| Recurso: |
SCIELO |
|
